SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

SANCHEZ R, César. Vejez y cáncer de mama, el desafío del siglo 21. Rev. méd. Chile [online]. 2012, vol.140, n.5, pp. 649-658. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872012000500015.

    1. Censo de Población y Vivienda. Instituto Nacional de Estadística. 2002. [ Links ]

    2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics 2008. CA Cancer J Clin 2008; 58: 71-96. [ Links ]

    3. http://portal.sernam.cl/?m=sp & i=1723#. Visitado octubre 2011. [ Links ]

    4. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmeno-pausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-92. [ Links ]

    5. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med 1999; 341: 2061-7. [ Links ]

    6. Kimmick G, Muss HB. Breast cancer in older patients. Semin Oncol 2004; 31: 234-48. [ Links ]

    7. Hanson LC, Muss HB. Cancer in the oldest old: making better treatment decisions. J Clin Oncol 2010; 28: 1975-6. [ Links ]

    8. Depinho RA. The age of cancer. Nature 2000; 408: 248-54. [ Links ]

    9. Martin GM, Oshima J. Lessons from human progeroid syndromes. Nature 2000; 408: 263-6. [ Links ]

    10. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8. [ Links ]

    11. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32. [ Links ]

    12. Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U, et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002; 34: 1318-30. [ Links ]

    13. Oller AR, Rastogi P, Morgenthaler S, Thilly WG. A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat Res 1989; 216: 149-61. [ Links ]

    14. Ershler WB, Longo DL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 1997; 89: 1489-97. [ Links ]

    15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. [ Links ]

    16. Haber DA. Telomeres, cancer, and immortality. N Engl J Med 1995; 332: 955-6. [ Links ]

    17. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-60. [ Links ]

    18. Schneider EL, Mitsui Y. The relationship between in vitro cellular aging and in vivo human age. Proc Natl Acad Sci U S A 1976; 73: 3584-8. [ Links ]

    19. Holmes FF, Wilson J, Blesch KS, Kaesberg PR, Miller R, Sprott R. Biology of cancer and aging. Cancer 1991; 68: 2525-6. [ Links ]

    20. Campisi J. Suppressing cancer: the importance of being senescent. Science 2005; 309: 886-7. [ Links ]

    21. Herman JG, BayliN SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54. [ Links ]

    22. Stone RM, O'Donnell Mr, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; 98-117. [ Links ]

    23. Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003; 53: 227-44. [ Links ]

    24. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81. [ Links ]

    25. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-4. [ Links ]

    26. Slamon DJ, Leyland-Jones B, Shak E, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 2001; 344: 783-92. [ Links ]

    27. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004; 9: 617-32. [ Links ]

    28. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-717. [ Links ]

    29. Taylor SG 4th, Gelman RS, Falkson G, Cummings FJ. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986; 104: 455-61. [ Links ]

    30. Vogel CL, East DR, Voigt W, Thomsen S. Response to tamoxifen in estrogen receptor-poor metastatic breast cancer. Cancer 1987; 60: 1184-9. [ Links ]

    31. Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 2003; 9: 460s-7s. [ Links ]

    32. Rodríguez Lajusticia L, Martín Jiménez M, López-Tarruella Cobo S. Endocrine therapy of metastatic breast cancer. Clin Transl Oncol 2008; 10: 462-7. [ Links ]

    33. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88. [ Links ]

    34. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-42. [ Links ]

    35. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 842-8. [ Links ]

    36. Ellis M, Gao F, Dehdashti F, Jeffe D, Marcom P, Carey L, et al. Lower-dose vs high-dose oral estradiol therapy of hormonereceptor-positive, aromatase inhibitor-resistant advanced breastcancer: a phase 2 randomized study. JAMA 2009; 302: 774-80. [ Links ]

    37. Balducci L, Extermann M, Carreca I. Management of breast cancer in the older woman. Cancer Control 2001; 8: 431-41. [ Links ]

    38. Wasil T, Lichtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist 2005; 10: 602-12. [ Links ]

    39. Balducci L, Beghe C. Pharmacology of Chemotherapy in the Older Cancer Patient. Cancer Control 1999; 6: 466-70. [ Links ]

    40. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23: 8597-605. [ Links ]

    41. Christman K, Muss HB, Case Ld, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 1992; 268: 96-7. [ Links ]

    42. Gelman RS, Taylor SG 4th. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2: 1404-13. [ Links ]

    43. Balducci L, Extermann M. Management of Cancer in the Older Person: A Practical Approach. Oncologist 2000; 5: 224-37. [ Links ]

    44. Horgan A, Leighl N, Coate L, Liu G, Palepu P, Knox J, Perera N, et al. Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology Setting: A Pilot Study. Am J Clin Oncol 2011 Mar 17. [Epub ahead of print] [ Links ]

    45. Balducci L, Extermann M. Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 2000; 14: 1-16. [ Links ]

    46. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457-65. [ Links ]

    47. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-10. [ Links ]

    48. Hensley M, Hagerty K, Kewalramani T, Green D, Meropol N, Wasserman T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27: 127-45. [ Links ]

    49. www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Visitado julio de 2011. [ Links ]

    50. Vogel C, O'rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10: 397-402. [ Links ]

    51. Sorio R, Robieux I, Galligioni E, Freschi A, Colussi Am, Crivellari D, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33: 301-3. [ Links ]

    52. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004; 30: 333-42. [ Links ]

    53. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155-61. [ Links ]

    54. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439-60. [ Links ]

    55. Martín M, Esteva FJ, Alba E, Khandheria B, Pérez-Isla L, García-Sáenz JA, et al. Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. Oncologist 2009; 14: 1-11. [ Links ]

    56. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005; 16:687-95. [ Links ]

    57. Henrich D, Bergner R, Hoffmann M, Schanz J, Landmann T, Uppenkamp M, et al. Ibandronate in the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure. Support Care Cancer 2005; 13: 463; 21a-150a. [ Links ]

    58. Gridelli C. The Use of Bisphosphonates in Elderly Cancer Patients. Oncologist 2007; 12: 62-71. [ Links ]

    59. Stopeck A, Lipton A, Body J, Steger G, Tonkin K, De Boer R, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-9. [ Links ]

    60. Leonard RC, Untch M, Von Koch F. Management of anaemia in patients with breast cancer: role of epoetin. Ann Oncol 2005; 16:817-24. [ Links ]

    61. Marín PP. The situation of the elderly in Chile. Rev Med Chile 1998; 125: 1207-12. [ Links ]

    62. Marín PP, Hoyl T, Gac H, Carrasco M, Duery P, Petersen K, et al. Assessment of 1497 Chilean nursing home residents, using the Resource Utilization Group method, RUG T-18. Rev Med Chile 2004; 132: 701-6. [ Links ]